Inflammatory Bowel Diseases Elevate the Risk of Developing Acute Pancreatitis

Supplemental digital content is available in the text. Objectives Increasing data suggest that acute pancreatitis (AP) occurs more frequently among patients with inflammatory bowel diseases (IBDs) than in the non-IBD population; however, currently no comprehensive meta-analysis is available. Methods Systematic literature search was conducted in 4 major databases. We included observational studies sampling from the general population. Basic study characteristics and crude incidences of AP were extracted. Pooled odds ratios (ORs) with 95% confidence interval (CIs) were calculated using the random-effects model. Subgroups were set up by Crohn disease and ulcerative colitis. Heterogeneity was tested with I2 statistics. Results Eight studies were eligible for the analysis. The odds of AP were 3 times higher in IBD (OR, 3.11; 95% CI, 2.93–3.30; I2, 0.0%), significantly higher in Crohn disease than in ulcerative colitis (P < 0.001; OR, 4.12 vs OR, 2.61; I2, 0.0%). The pooled annual incidence of AP in IBD was 210/100,000 person-years (95% CI, 84–392/100,000 person-years; I2, 98.66%). Conclusions We confirmed that IBD elevates the risk of AP and of 100,000 IBD patients 210 AP cases are to be expected annually. Therefore, it is important to include pancreatic enzyme level measurements and radiological investigations in the workup of IBD patients with acute abdominal pain.

[1]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[2]  Douglas G. Altman,et al.  Analysing data and undertaking meta‐analyses , 2019, Cochrane Handbook for Systematic Reviews of Interventions.

[3]  P. Hegyi,et al.  Computed Tomography Severity Index vs. Other Indices in the Prediction of Severity and Mortality in Acute Pancreatitis: A Predictive Accuracy Meta-analysis , 2019, Front. Physiol..

[4]  T. Iida,et al.  The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease , 2019, Journal of clinical medicine.

[5]  J. Ludvigsson,et al.  Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. , 2019, The Lancet. Child & adolescent health.

[6]  A. Osvaldt,et al.  A systematic review and meta-analysis of the aetiology of acute pancreatitis. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  S. Vavricka,et al.  Extraintestinal manifestations in inflammatory bowel disease – epidemiology, genetics, and pathogenesis , 2019, Expert review of gastroenterology & hepatology.

[8]  Mi-Sook Kim,et al.  Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients , 2018, PloS one.

[9]  Cheng-Li Lin,et al.  Association between Inflammatory Bowel Disease and Cholelithiasis: A Nationwide Population-Based Cohort Study , 2018, International journal of environmental research and public health.

[10]  G. Rogler,et al.  Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases , 2017, PloS one.

[11]  P. Rufo,et al.  The Role of Environmental Factors in the Pathogenesis of Inflammatory Bowel Diseases: A Review , 2017, JAMA pediatrics.

[12]  J. Byeon,et al.  Clinical course of ulcerative colitis patients who develop acute pancreatitis , 2017, World journal of gastroenterology.

[13]  J. Gervain,et al.  Prospective, Multicentre, Nationwide Clinical Data from 600 Cases of Acute Pancreatitis , 2016, PloS one.

[14]  E. Ehrenpreis,et al.  Inpatient Costs for Patients with Inflammatory Bowel Disease and Acute Pancreatitis , 2016, Inflammatory bowel diseases.

[15]  Cheng-Li Lin,et al.  Inflammatory bowel disease on the risk of acute pancreatitis: A population‐based cohort study , 2016, Journal of gastroenterology and hepatology.

[16]  H. Tilg,et al.  The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[17]  N. Teich,et al.  Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity , 2015, Journal of Crohn's & colitis.

[18]  G. Kaplan,et al.  Clinical predictors of thiopurine-related adverse events in Crohn's disease. , 2015, World journal of gastroenterology.

[19]  G. Faich,et al.  Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database , 2015, Current medical research and opinion.

[20]  G. Guyatt,et al.  Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients , 2015, BMJ : British Medical Journal.

[21]  A. Day,et al.  Thiopurine-induced pancreatitis in inflammatory bowel diseases , 2015, Expert review of gastroenterology & hepatology.

[22]  P. Hegyi,et al.  [Acute pancreatitis. Evidence-based practice guidelines, prepared by the Hungarian Pancreatic Study Group]. , 2015, Orvosi hetilap.

[23]  V. Santharam,et al.  Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study , 2013, Frontline Gastroenterology.

[24]  C. Bombardier,et al.  Assessing Bias in Studies of Prognostic Factors , 2013, Annals of Internal Medicine.

[25]  E. Kuipers,et al.  Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. , 2012, World journal of gastroenterology.

[26]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[27]  J. Mate,et al.  Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease. , 2011, Gastroenterologia y hepatologia.

[28]  E. van Geenen,et al.  Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon , 2010, Alimentary pharmacology & therapeutics.

[29]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[30]  J. Gisbert,et al.  Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine‐induced pancreatitis , 2008, Alimentary pharmacology & therapeutics.

[31]  E. Dimagno,et al.  New advances in acute pancreatitis , 2007, Current opinion in gastroenterology.

[32]  S. Gallus,et al.  Incidence and risk factors for gallstones in patients with inflammatory bowel disease: A large case‐control study , 2007, Hepatology.

[33]  L. Alfredsson,et al.  Acid‐suppressing drugs and gastroesophageal reflux disease as risk factors for acute pancreatitis—results from a Swedish Case‐Control Study , 2006, Pharmacoepidemiology and drug safety.

[34]  J. Schölmerich,et al.  Increased insulin resistance and &bgr; cell activity in patients with Crohn's disease , 2006, Inflammatory bowel diseases.

[35]  J. Mclaughlin,et al.  Statins and the risk of acute pancreatitis: a population‐based case–control study , 2006, Alimentary pharmacology & therapeutics.

[36]  S. Chari,et al.  Acute Pancreatitis in Patients With Crohn's Disease: Clinical Features and Outcomes , 2005, Inflammatory bowel diseases.

[37]  J. J. Homan van der Heide,et al.  Increased incidence of azathioprine‐induced pancreatitis in Crohn's disease compared with other diseases , 2004, Alimentary pharmacology & therapeutics.

[38]  H. Sørensen,et al.  Inflammatory Bowel Diseases, 5-Aminosalicylic Acid and Sulfasalazine Treatment and Risk of Acute Pancreatitis: A Population-Based Case-Control Study , 2004, American Journal of Gastroenterology.

[39]  M. Eichelbaum,et al.  Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. , 2002, Pharmacogenetics.

[40]  L. Gullo,et al.  Acute Pancreatitis in Five European Countries: Etiology and Mortality , 2002, Pancreas.

[41]  H. Sørensen,et al.  Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. , 1999, Scandinavian journal of gastroenterology.

[42]  P. Malfertheiner,et al.  Management of severe acute pancreatitis. , 1993, The Gastroenterologist.

[43]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[44]  R. Jian,et al.  Idiopathic pancreatitis associated with inflammatory bowel disease , 1985, Digestive Diseases and Sciences.

[45]  C. DiMaio,et al.  Inflammatory Bowel Disease and Pancreatitis: A Review. , 2016, Journal of Crohn's & colitis.

[46]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[47]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[48]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[49]  J. A. Bargen,et al.  Pancreatic lesions associated with chronic ulcerative colitis. , 1950, Archives of pathology.